EUCANCan will receive 5,999,453.75 EUR of funding from the European Union’s Horizon 2020 research and innovation programme as well as funding from the Canadian Institutes of Health Research over the duration of four years, starting from January 1st 2019.

Horizon 2020

Horizon 2020 is the European Commission funding programme to support research and innovation in the European Union. This framework programme has a budget of about 77,028 billion euros for a 7 year period (2014-2020) to support research, technological development and relevant innovative initiatives.

Horizon 2020 groups, compliments and continues previous work achieved during the 7th Framework Programme for Research and Innovation (2007-2013), strengthens innovation actions from the Competitiveness and Innovation Framework Programme and the European Institute of Innovation and Technology actions.

Canadian Institutes of Health Research

The Canadian Institutes of Health Research (CIHR) is Canada’s federal funding agency for health research. Composed of 13 Institutes, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system. CIHR was created in 2000 under the authority of the Canadian Institutes of Health Research Act. It is an independent agency and is accountable to Parliament through the Minister of Health. CIHR provides leadership and support to health researchers and trainees across Canada.

Network Partners

Six projects have been selected for funding under the Horizon2020 call SC1-BHC-05-2018 “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” designed to build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing humanomics data that will create a framework for long-term cooperation. In order to do so, the programme aims to enhance and standardize data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide.


Funding sum: € 6,531,275
Coordinator: Heidelberg University Hospital
RECODID stands for Integrated human data repositories for infectious disease-related international cohorts to foster personalized medicine approaches to infectious disease research. The project goes beyond public health emergencies and developes new methods and data architectures for within- and cross-cohort harmonization of laboratory and clinical and epidemiological data. RECODID builds on existing infrastructures and partnerships to develop a sustainable model for the storage, curation, and analyses of the complex data sets collected by infectious disease (ID)-related cohorts. While ID cohorts collect both clinical-epidemiological (CE) and OMICS data, storage and analysis of these data remains separate and developing the infrastructure for housing and analyzing OMICS data is not feasible for individual studies. As global investment in OMICS research increases exponentially, researchers and communities need to address the widening gap between high- and low-and-middle-income countries (LMIC) in terms of whose OMICS data is being shared and analyzed and who, consequently, benefits from advances made possible by OMICS data. RECODID will develop the data architecture and methods, governance, and linkages between biobanks and data repositories needed to connect data generators to the open science community to ensure that addressing IDs that disproportionately affect LMIC becomes part of the personalized medicine revolution.


Funding sum: €5,395,2923.50
Coordinator: University of Pompeu Fabra (UPF)
euCanSHare is an EU-Canada joint infrastructure for next-generation multi-Study Heart research. The 4-year Horizon 2020 project is coordinated by the University of Pompeu Fabra (UPF) in Spain, and includes prestigious universities, research centres and SMEs in Canada and Europe (Germany, Italy, Netherlands, United Kingdom, Belgium, Spain, France, Austria and Finland). The project aims at developing a translational research platform for cardiovascular data sharing between the European Union (EU) and Canada. Once established, researchers will benefit from a consolidated one-stop, integrated data shop to perform efficient and effective research based on data-driven approaches linking molecular, imaging, functional and clinical data. The end goal is tailor-made patient treatment and better cardiovascular disease outcomes. The project integrates more than 35 Canadian and European cohorts that make up over 1 million records. These cohorts include -omics (genomics, transcriptomics, metabolomics, just to name a few) cardiac imaging and clinical data.


Coordinator: University Medical Center Groningen (UMCG)
EUCAN-Connect (A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health) will enable large-scale integrated cohort data analysis for personalized and preventive healthcare across EU and Canada. This will be based on an open, scalable data platform for cohorts, researchers and networks, incorporating FAIR principles (Findable, Accessible, Interoperable, Reusable) for optimal reuse of existing data, and building on maturing federated technologies, with sensitive data kept locally and only results being shared and integrated, in line with key ELSI and governance guidelines.

iReceptor Plus

iReceptor Plus (Architecture and tools for the query of antibody and t-cell receptor sequencing data repositories for enabling improved personalized medicine and immunotherapy) aims to facilitate the sharing of AIRR-seq data among multiple institutions for a better understanding of the causes of infectious and autoimmune diseases and cancer. Its consortium of researchers from EU and Canada will address several key challenges to the optimal sharing of AIRR-seq data among public and industrial partners, such as patient privacy, intellectual property, data integration and harmonisation, to support early detection, identification of novel therapies and possibly reduce the social and economic burden of these diseases worldwide.